GLP-1 Receptor Agonists: Alternatives to Prandial Insulin

Provided by Horizon CME.

This activity is supported by an educational grant provided by Sanofi US.

Scroll to the Bottom of this Information to Begin this Course

Release date: October 1, 2016

Valid through: October 1, 2017

Specialty: Endocrinology

Topic: GLP-1 Receptor Agonists

Media: Internet

Estimated Time to Complete Activity: 60 minutes

Target Audience

This activity has been designed to meet the educational needs of NPs, PAs and other health care professionals involved in the care of patients with diabetes.

Program Overview

This webcast will educate clinicians on the contribution of post-prandial glucose to A1C and its impact on diabetes complications. Additionally, the activity will discuss the efficacy of GLP-1 receptor agonists for the management of post-prandial hyperglycemia, clinical inertia and strategies for timely intensification of anti-hyperglycemic therapy and strategies to overcome barriers to achieving postprandial glucose control in patients on basal insulin.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the contribution of postprandial glucose (PPG) to A1C and its effect on complications
  • Describe the mechanism and efficacy of GLP-1 receptor agonists for the management of PPG
  • Implement strategies for the timely intensification of therapy in patients with type 2 diabetes
  • Identify and implement strategies to overcome barriers to achieving postprandial glucose control in patients taking basal insulin

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Dace Trence, MD, FACE

Dace Trence, MD, FACE

Professor of Medicine
Director, Diabetes Care Center
University of Washington
Seattle, WA

Faculty Bio
Dace L. Trence, MD, FACE, is currently Director of the Diabetes Care Center and Professor of Medicine at the University of Washington Medical Center in Seattle. She is also the University of Washington Endocrine Fellowship Program Director and Director of Endocrine Days, a medical education program for endocrinologists practicing in the Pacific Northwest. She currently serves on the American Association of Clinical Endocrinologists Board of Directors, chairing the AACE Publications Committee and co-chairing AACE CME committee. She has been on the editorial boards of several journals including Clinical Diabetes. She has had articles published in JCEM, JAMA, Diabetes Care and is a co-author of Optimizing Diabetes Care for the Practitioner. Her current interests include improving educational processes in diabetes self-management and clinical training of health care professionals.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Horizon CME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

Dace Trence, MD, FACE
  • Stock/Bond: Sanofi and Medtronic

William J. Elliott, M.D., Ph.D, Professor of Preventive Medicine, Internal Medicine and Pharmacology, Head, Division of Pharmacology, Pacific Northwest University of Health Sciences provided external review for this activity. He has served on an Advisory Board for Insyght Interactive, Inc.

Vivian Fonseca, MD, Professor of Medicine and Pharmacology, Tullis Tulane Alumni Chair in Diabetes, Chief, Section of Endocrinology, Tulane University Health Sciences Center served as Content Chair for this activity. He has received research grants from Asahi, Bayer, Endo Barrier, Gilead Sciences, Takeda, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Astra Zeneca, Amgen and Jansen. He has served as a consultant for fee for Takeda, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Astra-Zeneca, Amgen and Jansen.

Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Instructions for Participation and Credit

By reviewing the course content and successfully completing the pre-test, post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credit™. Statement of credit will be available to print from your user history page.

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the pre-test, post-test and activity evaluation.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.